Source comparison
Continuous use versus cycling: what the trials documented
The community 8-on/8-off pattern is one approach; the clinical record describes another. In the Phase 3 program, tesamorelin was dosed at 2 mg subcutaneously every day for 52 continuous weeks with no scheduled breaks. IGF-1 reached its elevated plateau by week
This comparison does not assign a generated winner or score.
- The community 8-on/8-off pattern is one approach; the clinical record describes another. In the Phase 3 program, tesamorelin was dosed at 2 mg subcutaneously every day for 52 continuous weeks with no scheduled breaks. IGF-1 reached its elevated plateau by week 26 and was maintained at that level through week 52, and visceral-fat reduction was sustained across the full year — the trials documented no tachyphylaxis (no loss of response over time) on continuous daily dosing (Falutz et al., 2007; 52-week extension, 2010). Trial data also documented that visceral fat re-accumulated after dosing stopped.
- Community sources therefore describe two documented paths. Cycled use (commonly 8 weeks on, 8 weeks off) is typically described in the context of cost management and letting IGF-1 normalize between blocks. Continuous use mirrors the FDA-approved protocol, where the trial evidence for a sustained, non-attenuating response is strongest. In the trials, IGF-1 was monitored against the laboratory reference range, and published protocols described dose reduction when IGF-1 rose above it.